Literature DB >> 10540155

Counter-regulatory effect of sodium butyrate on tumour necrosis factor-alpha (TNF-alpha)-induced complement C3 and factor B biosynthesis in human intestinal epithelial cells.

A Andoh1, Y Fujiyama, K Hata, Y Araki, H Takaya, M Shimada, T Bamba.   

Abstract

The various biological activities of butyrate have been well documented. In this study, we tested the effects of butyrate on TNF-alpha-induced complement C3 and factor B biosynthesis in human intestinal epithelial cells. The biosynthesis of C3, factor B and IL-8 was evaluated at the protein and mRNA levels. To evaluate transcriptional activation, the nuclear run-on assay was performed. The transcription factor-DNA binding activity was assessed by an electrophoretic gel mobility shift assay (EMSA). In the intestinal epithelial cell lines HT-29, T84 and Caco-2, sodium butyrate enhanced TNF-alpha-induced C3 secretion, but suppressed TNF-alpha-induced factor B and IL-8 secretion. Nuclear run-on assay revealed that transcriptional regulatory mechanisms are involved in the effects of sodium butyrate. The EMSAs indicated that sodium butyrate suppressed TNF-alpha-induced nuclear factor (NF)-kappaB- and activation protein (AP)-1-DNA binding activity, but enhanced TNF-alpha-induced activation of CCAAT/enhancer-binding protein (C/EBP)beta (NF-IL-6)-DNA binding activity. Sodium butyrate induced a counter-regulatory effect on TNF-alpha-induced C3 and factor B biosynthesis in human intestinal epithelial cells. Butyrate action has been discussed with its activity to induce histone hyperacetylation, but its counter-regulatory effect on complement biosynthesis may be closely associated with the modulation of transcription factor activation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10540155      PMCID: PMC1905403          DOI: 10.1046/j.1365-2249.1999.01038.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  46 in total

Review 1.  The pathophysiology of tumor necrosis factors.

Authors:  P Vassalli
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

2.  Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis.

Authors:  W Scheppach; H Sommer; T Kirchner; G M Paganelli; P Bartram; S Christl; F Richter; G Dusel; H Kasper
Journal:  Gastroenterology       Date:  1992-07       Impact factor: 22.682

3.  Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease.

Authors:  E J Breese; C A Michie; S W Nicholls; S H Murch; C B Williams; P Domizio; J A Walker-Smith; T T MacDonald
Journal:  Gastroenterology       Date:  1994-06       Impact factor: 22.682

4.  Synergistic transcriptional activation of the IL-8 gene by NF-kappa B p65 (RelA) and NF-IL-6.

Authors:  C Kunsch; R K Lang; C A Rosen; M F Shannon
Journal:  J Immunol       Date:  1994-07-01       Impact factor: 5.422

5.  Tumor necrosis factor alpha and interferon gamma synergistically induce interleukin 8 production in a human gastric cancer cell line through acting concurrently on AP-1 and NF-kB-like binding sites of the interleukin 8 gene.

Authors:  K Yasumoto; S Okamoto; N Mukaida; S Murakami; M Mai; K Matsushima
Journal:  J Biol Chem       Date:  1992-11-05       Impact factor: 5.157

6.  Effect of interferon-gamma on complement gene expression in different cell types.

Authors:  D F Lappin; D Guc; A Hill; T McShane; K Whaley
Journal:  Biochem J       Date:  1992-01-15       Impact factor: 3.857

7.  Differential cytokine expression by human intestinal epithelial cell lines: regulated expression of interleukin 8.

Authors:  L Eckmann; H C Jung; C Schürer-Maly; A Panja; E Morzycka-Wroblewska; M F Kagnoff
Journal:  Gastroenterology       Date:  1993-12       Impact factor: 22.682

8.  Participation of the transcription factor C/EBP delta in the acute-phase regulation of the human gene for complement component C3.

Authors:  T S Juan; D R Wilson; M D Wilde; G J Darlington
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

9.  Effect of short-chain fatty acids on the human colonic mucosa in vitro.

Authors:  W Scheppach; P Bartram; A Richter; F Richter; H Liepold; G Dusel; G Hofstetter; J Rüthlein; H Kasper
Journal:  JPEN J Parenter Enteral Nutr       Date:  1992 Jan-Feb       Impact factor: 4.016

10.  Distinct modes of transcription read through or terminate at the c-myc attenuator.

Authors:  S Roberts; D L Bentley
Journal:  EMBO J       Date:  1992-03       Impact factor: 11.598

View more
  26 in total

Review 1.  Regulation of epithelial cell functions by the intestinal milieu.

Authors:  Tadao Bamba
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

Review 2.  Therapeutic approaches targeting intestinal microflora in inflammatory bowel disease.

Authors:  Akira Andoh; Yoshihide Fujiyama
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

Review 3.  The protective potency of probiotic bacteria and their microbial products against enteric infections-review.

Authors:  J F J G Koninkx; J J Malago
Journal:  Folia Microbiol (Praha)       Date:  2008-07-27       Impact factor: 2.099

4.  Propionibacterium freudenreichii component 1.4-dihydroxy-2-naphthoic acid (DHNA) attenuates dextran sodium sulphate induced colitis by modulation of bacterial flora and lymphocyte homing.

Authors:  Y Okada; Y Tsuzuki; J Miyazaki; K Matsuzaki; R Hokari; S Komoto; S Kato; A Kawaguchi; S Nagao; K Itoh; T Watanabe; S Miura
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

5.  Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis.

Authors:  Akira Andoh; Hirotsugu Imaeda; Tomoki Aomatsu; Osamu Inatomi; Shigeki Bamba; Masaya Sasaki; Yasuharu Saito; Tomoyuki Tsujikawa; Yoshihide Fujiyama
Journal:  J Gastroenterol       Date:  2011-01-21       Impact factor: 7.527

6.  Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis.

Authors:  Yasushi Yoshimatsu; Akihiro Yamada; Ryuichi Furukawa; Koji Sono; Aisaku Osamura; Kentaro Nakamura; Hiroshi Aoki; Yukiko Tsuda; Nobuo Hosoe; Nobuo Takada; Yasuo Suzuki
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

7.  Butyrate stimulates IL-32alpha expression in human intestinal epithelial cell lines.

Authors:  Ayako Kobori; Shigeki Bamba; Hirotsugu Imaeda; Hiromitsu Ban; Tomoyuki Tsujikawa; Yasuharu Saito; Yoshihide Fujiyama; Akira Andoh
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

8.  The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease.

Authors:  T Sugihara; A Kobori; H Imaeda; T Tsujikawa; K Amagase; K Takeuchi; Y Fujiyama; A Andoh
Journal:  Clin Exp Immunol       Date:  2010-01-19       Impact factor: 4.330

9.  Cellobiose Prevents the Development of Dextran Sulfate Sodium (DSS)-Induced Experimental Colitis.

Authors:  Takashi Nishimura; Akira Andoh; Takayoshi Hashimoto; Ayako Kobori; Tomoyuki Tsujikawa; Yoshihide Fujiyama
Journal:  J Clin Biochem Nutr       Date:  2010-02-24       Impact factor: 3.114

10.  Butyrate regulates the expression of pathogen-triggered IL-8 in intestinal epithelia.

Authors:  Meiqian Weng; W Allan Walker; Ian R Sanderson
Journal:  Pediatr Res       Date:  2007-11       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.